Indeed, our findings encourage an extension of clinical trials of mTOR inhibitors from patients presenting genetic forms of autism-related disorder, like tuberous sclerosis (Auerbach et al, 2011; Ehninger et al, 2008; Ehninger & Silva, 2011), to more numerous populations of schizophrenic patients. This evidence concerns the gene MTOR and tuberous sclerosis.